Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evgenia Aga

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 5, 2011
A randomized trial of interleukin-2 during withdrawal of antiretroviral treatmentRonald J Bosch, Richard B Pollard, Alan Landay, et al.
AIDS Research and Therapy|August 7, 2010
Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)Ronald J Bosch, Richard B Pollard, Alan Landay, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 4, 2011
Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infectionElizabeth Connick, Ronald J Bosch, Evgenia Aga, et al.
The Journal of Infectious Diseases|July 28, 2011
Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapyBabafemi Taiwo, Sebastien Gallien, Evgenia Aga, et al.
Antiviral Therapy|October 15, 2016
Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settingsMitch M Matoga, Mina C Hosseinipour, Evgenia Aga, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 6, 2014
Drug susceptibility and resistance mutations after first-line failure in resource limited settingsCarole L Wallis, Evgenia Aga, Heather Ribaudo, et al.
Virology|June 8, 2018
Associations between HIV-1 DNA copy number, proviral transcriptional activity, and plasma viremia in individuals off or on suppressive antiretroviral therapyFeiyu Hong, Jana L Jacobs, Evgenia Aga, et al.
AIDS (London, England)|August 22, 2009
Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatmentPaul Volberding, Lisa Demeter, Ronald J Bosch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 25, 2016
Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption TrialsGraham C Treasure, Evgenia Aga, Ronald J Bosch, et al.
Journal of Clinical Microbiology|January 15, 2016
Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNAFeiyu Hong, Evgenia Aga, Anthony R Cillo, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|February 5, 2011
A randomized trial of interleukin-2 during withdrawal of antiretroviral treatmentRonald J Bosch, Richard B Pollard, Alan Landay, et al.
AIDS Research and Therapy|August 7, 2010
Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)Ronald J Bosch, Richard B Pollard, Alan Landay, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 4, 2011
Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infectionElizabeth Connick, Ronald J Bosch, Evgenia Aga, et al.
The Journal of Infectious Diseases|July 28, 2011
Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapyBabafemi Taiwo, Sebastien Gallien, Evgenia Aga, et al.
Antiviral Therapy|October 15, 2016
Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settingsMitch M Matoga, Mina C Hosseinipour, Evgenia Aga, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 6, 2014
Drug susceptibility and resistance mutations after first-line failure in resource limited settingsCarole L Wallis, Evgenia Aga, Heather Ribaudo, et al.
Virology|June 8, 2018
Associations between HIV-1 DNA copy number, proviral transcriptional activity, and plasma viremia in individuals off or on suppressive antiretroviral therapyFeiyu Hong, Jana L Jacobs, Evgenia Aga, et al.
AIDS (London, England)|August 22, 2009
Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatmentPaul Volberding, Lisa Demeter, Ronald J Bosch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 25, 2016
Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption TrialsGraham C Treasure, Evgenia Aga, Ronald J Bosch, et al.
Journal of Clinical Microbiology|January 15, 2016
Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNAFeiyu Hong, Evgenia Aga, Anthony R Cillo, et al.
Pageof 5